Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

FDA approves new treatments for transthyretin-mediated amyloidosis-cardiomyopathy

News - May 13, 2019

Tafamidis meglumine and tafamidis capsules have received FDA approval for treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Lower risk of incident hospitalization for HF with higher adherence to plant-based diet

Literature - May 7, 2019 - Lara KM et al. - JACC 2019
In this cohort study higher adherence to plant-based dietary patterns was associated with lower risk of incident HHF in adults without CHD.

In this cohort study higher adherence to plant-based dietary patterns was associated with lower risk of incident HHF in adults without CHD.

Sex-specific differences in HFrEF patients using ARNI in real-world setting

Literature - Apr. 29, 2019 - Vicent L, et al. - Cardiology 2019
In a real-world cohort of HFrEF patients starting sacrubitril/valsartan, 29.5% were women. After 7 months NYHA functional class improvement was greater in women vs. men.

In a real-world cohort of HFrEF patients starting sacrubitril/valsartan, 29.5% were women. After 7 months NYHA functional class improvement was greater in women vs. men.

Prior pacemaker implantation associated with increased CV death and HF hospitalization in HFpEF

Literature - Apr. 24, 2019 - Shen L, et al. - JACC Heart Fail 2019

In a pooled analysis of 3 HFpEF trials, CV death and HF hospitalization were increased in HFpEF patients with prior pacemaker implantation compared to those without.

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019
Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.

ACC 2019 Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019
In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.

ACC 2019 In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.

Incidence, predictors and associated outcomes of EF change in HF patients

Literature - Apr. 3, 2019 - Savarese G et al. - JACC Heart Failure 2019
The SwedeHF register showed a change in ejection fraction (EF) over time across EF groups of HF patients, which was linked to adverse outcomes, particularly in those transitioning to and from HFrEF.

The SwedeHF register showed a change in ejection fraction (EF) over time across EF groups of HF patients, which was linked to adverse outcomes, particularly in those transitioning to and from HFrEF.

BNP and NT-proBNP provide prognostic information with comparable performance during ARNI therapy in HFrEF

Literature - Apr. 2, 2019 - Langeland Myhre P et al. - JACC 2019

Treatment with sacubitril/valsartan shifts BNP level distribution right-wards as compared to NT-proBNP levels, but both NPs could predict the risk of CV death or first hospitalization for HF in HFrEF patients.

Underuse and underdosing of HF medication in elderly HF patients

Literature - Apr. 1, 2019 - Veenis JF et al. - Eur Heart J 2019
A Dutch registry showed that elderly outpatient HFrEF and HFmrEF patients were treated less often with recommended types and dosages of HF medication than younger patients, and received less often ICD and CRT devices.

A Dutch registry showed that elderly outpatient HFrEF and HFmrEF patients were treated less often with recommended types and dosages of HF medication, and received less often ICD and CRT devices.

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019
Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.

ACC 2019 Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.

Central and peripheral exercise-related factors independently associated with presence of HFpEF

Literature - Mar. 21, 2019 - Wolsk E et al. - JACC Heart Failure 2019

Pulmonary capillary wedge pressure (PCWP), BMI and stroke volume were independently associated with the presence of HFpEF, compared with healthy subjects exercising at the same workloads.

Echocardiographic predictors of clinical outcomes in patients with HF and severe secondary mitral regurgitation

News - Mar. 21, 2019

ACC 2019 In an echocardiography substudy of the COAPT trial, predictors of poor outcomes were studied in HF patients with severe secondary mitral regurgitation.